Key Facts
Eli Lilly (NYSE: LLY) reported a substantial revenue increase of 45% in 2025, reaching over $65 billion, with a net income just under $21 billion and a profit margin of approximately 32%. It has multiple approved GLP-1 products, including the weight-loss pill Foundayo, and recently gained FDA approval for its Alzheimer’s drug Kisunla.
Viking Therapeutics (NASDAQ: VKTX), valued at just $4 billion, is developing a GLP-1 drug, VK2735, which shows promising results in clinical trials, demonstrating around 15% weight loss over 13 weeks. This injectable version is currently in phase 3 trials, while the oral version is set to begin phase 3 trials later this year.
Both companies highlight significant opportunities in the GLP-1 market, which has the potential to generate billions in revenue as competition increases. However, Eli Lilly is considered a safer investment, while Viking Therapeutics presents a higher risk with potential for higher returns if VK2735 receives approval.
